CONTACT US   |  (864) 397-5101

3 ways Biden’s COVID-19 approach could impact medtech

While former Vice President Joe Biden and the team he builds won’t take office for another two months, the campaign’s plans for COVID-19healthcare and other policy areas offer clues to how changing tides in Washington may impact the medtech industry.

In approaching the top task at hand — getting the pandemic under control — the Democrat’s plan includes proposals with implications for the industry, from how diagnostic testing is covered to access to telemedicine services.

In some ways, the act of swapping out administrations, regardless of who’s in power, means device makers can anticipate shifts at key government agencies like the FDA.

Read on for the full article from Medtech Dive.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.